Peptide Therapeutics Market Size, Share, Growth Analysis, By Application(Cancer, Metabolic, Cardiovascular Disorder, Respiratory), By Type of Manufacturers(In-house, Outsourced), By Type(Generic, Innovative), By Route of Administration(Parenteral, Oral, Pulmonary, Mucosal), By Synthesis Technology(Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology), By Region - Industry Forecast 2024-2031

Peptide Therapeutics Market Drivers

Rising Incidence of Chronic Diseases 

• Poor lifestyle choices and growing adoption of unhealthy habits have lead to a major surge in incidence of chronic diseases around the world. As prevalence of diabetes, cancer, and other diseases rises, so does the need for better treatment for the same also rises. Low toxicity of peptide therapeutics makes them a preferred choice for treatment for multiple chronic diseases.  

Rising Use of Targeted Therapies 

• Healthcare professionals around the world are focusing on using targeted therapies to treat and manage various types of disease indications as prevalence of chronic diseases rises. Peptide therapeutics are highly efficient in targeting specific cell receptors, which makes them a mainstay in targeted therapy use.  

Restraints 

Limited Oral Bioavailability 

• Peptides can be easily digested if consumed orally and this is a key issue that is limiting the scope of administration of peptide therapeutics orally. This leads to peptide therapeutics being administered through invasive procedures such as injections, which not many people opt for as most prefer non-invasive treatments.

High Production Costs 

• Manufacturing and preparing peptide therapeutics is a complex task that requires high precision. Moreover, the complexity of peptide structures also adds up to the complexity of manufacturing. All of these factors result in high costs of production for peptide therapeutics and thereby impede market growth potential as well.